For decades, the standard path for breast reconstruction following a mastectomy has been a binary choice: synthetic...
Muslim
London, UK – October 8, 2026 – Despite significant strides in addressing women’s health inequities, a critical...
London, UK – [Insert Date] – AstraZeneca, through its rare disease arm Alexion Pharmaceuticals, faces a significant...
Navigating the Post-Treatment Horizon: Breast Cancer Canada’s Fall Webinar Series Empowers Survivors
Navigating the Post-Treatment Horizon: Breast Cancer Canada’s Fall Webinar Series Empowers Survivors
For many breast cancer survivors, the conclusion of active treatment—chemotherapy, radiation, or surgery—is not the end of...
By [Your Name/Journalistic Staff], based on insights from Douglas Feil, NBCF Chief Program Officer Disclaimer: The following...
The transition from active cancer treatment to survivorship is often described by patients as one of the...
The biotechnology sector continues to navigate a complex landscape defined by high-stakes clinical data, evolving regulatory standards,...
Age-related hearing loss, medically termed presbycusis, has long been categorized as a monolithic condition—a generic, inevitable byproduct...
Introduction On July 23, 2026, the U.S. Department of Health and Human Services (HHS) finalized a sweeping...
The global biopharmaceutical landscape is undergoing a period of intense scrutiny and strategic recalibration. As regulatory agencies...
